HCG Partners with Trucan Diagnostics to Validate Advanced Cancer Diagnostic Tests

The collaboration seeks to validate a series of innovative diagnostic tests for detecting primary and recurrent/metastatic cancers, predicting therapy response, and monitoring treatment efficacy.  

HealthCare Global Enterprises (HCG) has announced a research partnership with Trucan Diagnostics, a healthcare startup specializing in advanced cancer diagnostics. 

The collaboration seeks to validate a series of innovative diagnostic tests for detecting primary and recurrent/metastatic cancers, predicting therapy response, and monitoring treatment efficacy.  

HCG and Trucan Diagnostics will jointly conduct validation studies on Trucan’s next-generation diagnostic tests. These tests integrate advanced technologies like next-generation sequencing and biomarker-based detection methods. 

The aim is to enhance the accuracy of cancer detection and optimize treatment strategies by predicting therapy outcomes before initiation and continuously monitoring treatment responses during chemotherapy or targeted therapy.  

Dr BS Ajaikumar, Executive Chairman of HCG, highlighted the significance of the partnership: “This collaboration brings together our expertise in oncology with Trucan’s innovative diagnostic solutions. Together, we aim to validate novel technologies that could redefine how cancers are detected and treated.”

The validation studies aim to generate comprehensive clinical data to support the tests' adoption in routine practice. This includes their ability to identify recurrent cancers earlier and assist oncologists in tailoring treatment strategies.  

Trucan Diagnostics’ biomarker-driven approach focuses on improving cancer detection beyond traditional methods. The company claims its tests enable oncologists to personalize treatment plans more effectively, avoid ineffective therapies, and reduce associated risks and costs.  

Rahul Sinha, CEO of Trucan Diagnostics, said, “Our diagnostic tests are designed to bridge gaps in cancer care by providing clinicians with precise, actionable data. This partnership with HCG ensures rigorous clinical validation, ensuring these solutions deliver measurable benefits for patients and providers alike.”